AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33118603 — intervention group
Group type: EXPERIMENTAL
Intervention: Central Sensitization Inventory Symptom Severity Calculator
Number of subjects: 2620
Study 35346485 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 to 100 mg)
Number of subjects: 134
Study 35346485 — intervention group
Group type: COMPARATOR
Intervention: Standard hypotensive treatment (ST)
Number of subjects: 134
Study 34127486 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) therapy
Number of subjects: 55
Study 34127486 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Life (CL) support without VR
Number of subjects: 55
Study 34127486 — intervention group
Group type: COMPARATOR
Intervention: Reference group (no intervention)
Number of subjects: 55
Study 34741544 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led MBSR therapy + regular diabetes education
Number of subjects: 100
Study 34741544 — intervention group
Group type: COMPARATOR
Intervention: Regular diabetes education
Number of subjects: 100
Study 34312221 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% occipital nerve block
Number of subjects: 0
Study 34312221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33280397 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-applied acupressure in combination with usual treatment
Number of subjects: 160
Study 33280397 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (Control)
Number of subjects: 160
Study 33919990 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin
Number of subjects: 0
Study 33331798 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical (combination of soy isoflavone, black cohosh, chasteberry, and evening primrose oil extracts)
Number of subjects: 101
Study 33331798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 33223141 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of sevoflurane
Number of subjects: 621
Study 33223141 — intervention group
Group type: COMPARATOR
Intervention: Lower doses of sevoflurane
Number of subjects: 621
Study 33714712 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care training (two additional training sessions)
Number of subjects: 80
Study 33714712 — intervention group
Group type: COMPARATOR
Intervention: Routine training (control group)
Number of subjects: 80
Study 32321713 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated risk model including clinical factors, genetic polymorphisms, and circulating biomarkers
Number of subjects: 1591
Study 32321713 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated risk model
Number of subjects: 1591
Study 32321713 — intervention group
Group type: EXPERIMENTAL
Intervention: Top risk percentile individuals
Number of subjects: 1591
Study 32321713 — intervention group
Group type: COMPARATOR
Intervention: Clinical factors alone
Number of subjects: 1591
Study 34666606 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatherhood intervention
Number of subjects: 12
Study 34666606 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative descriptive content analysis
Number of subjects: 12
Study 34590118 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 16
Study 34590118 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk (subgroup with similar initial gastric volume)
Number of subjects: 16
Study 34590118 — intervention group
Group type: COMPARATOR
Intervention: Infant formula
Number of subjects: 16
Study 34933343 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA sequencing (RNA‐seq)
Number of subjects: 173
Study 34265446 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophilic Esophagitis patients (n=21)
Number of subjects: 41
Study 34265446 — intervention group
Group type: COMPARATOR
Intervention: Eosinophilic Esophagitis patients (n=20)
Number of subjects: 41
Study 34265446 — intervention group
Group type: EXPERIMENTAL
Intervention: Males aged 13 years and older with EoE
Number of subjects: 41
Study 34265446 — intervention group
Group type: EXPERIMENTAL
Intervention: Female EoE patients
Number of subjects: 41
Study 34265446 — intervention group
Group type: EXPERIMENTAL
Intervention: Male EoE patients
Number of subjects: 41
Study 34265446 — intervention group
Group type: EXPERIMENTAL
Intervention: Both male and female EoE patients
Number of subjects: 41
Study 34875098 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (anodal over left inferior frontal gyrus)
Number of subjects: 23
Study 34875098 — intervention group
Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 23
Study 34875098 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 23
Study 33606739 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intra-abdominal pressure (P10-12, 10-12 mm Hg)
Number of subjects: 64
Study 33606739 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intra-abdominal pressure (P6-8, 6-8 mm Hg)
Number of subjects: 64
Study 32232615 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with 106 cfu/mL/kg Lactobacillus acidophilus
Number of subjects: 240
Study 32232615 — intervention group
Group type: COMPARATOR
Intervention: Control diet (0 cfu/mL/kg Lactobacillus acidophilus)
Number of subjects: 240
Study 34378545 — intervention group
Group type: EXPERIMENTAL
Intervention: Iris scan technology
Number of subjects: 699
Study 33244404 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional support
Number of subjects: 2064
Study 33244404 — intervention group
Group type: EXPERIMENTAL
Intervention: Social network support
Number of subjects: 2064
Study 33244404 — intervention group
Group type: COMPARATOR
Intervention: Physical activity
Number of subjects: 2064
Study 35696706 — intervention group
Group type: EXPERIMENTAL
Intervention: My Surgical Success (MSS)
Number of subjects: 133
Study 35696706 — intervention group
Group type: COMPARATOR
Intervention: Digital general health education (HE)
Number of subjects: 133
Study 34769656 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong Families programme (intervention group, n = 199)
Number of subjects: 292
Study 34769656 — intervention group
Group type: COMPARATOR
Intervention: Waitlist/control group (n = 93)
Number of subjects: 292
Study 32119591 — intervention group
Group type: EXPERIMENTAL
Intervention: lyophilized TAK-003 formulation
Number of subjects: 1002
Study 32119591 — intervention group
Group type: COMPARATOR
Intervention: liquid TAK-003 formulation
Number of subjects: 1002
Study 34980131 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus chemotherapy
Number of subjects: 270
Study 34980131 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 270
Study 32502713 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced retraining group
Number of subjects: 16
Study 32502713 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 32502713 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study 35889878 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligonol
Number of subjects: 38
Study 35889878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 32607803 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE‐CT (dynamic contrast‐enhanced computed tomography)
Number of subjects: 36
Study 32607803 — intervention group
Group type: COMPARATOR
Intervention: DCE‐MRI (dynamic contrast‐enhanced MRI)
Number of subjects: 36
Study 34331546 — intervention group
Group type: EXPERIMENTAL
Intervention: imSTROKE
Number of subjects: 611
Study 34331546 — intervention group
Group type: COMPARATOR
Intervention: RAPID
Number of subjects: 611
Study 34232211 — intervention group
Group type: EXPERIMENTAL
Intervention: CURCUGEN, a novel dispersible, 50% curcuminoids-concentrated turmeric extract
Number of subjects: 0
Study 34232211 — intervention group
Group type: EXPERIMENTAL
Intervention: CURCUGEN
Number of subjects: 0
Study 34232211 — intervention group
Group type: COMPARATOR
Intervention: C-95, standard curcumin reference product
Number of subjects: 0
Study 35932073 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led integrative medicine-based structured education program (4 weeks)
Number of subjects: 128
Study 35932073 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 128
Study 33423620 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET) consisting of aerobic, strengthening and stretching exercises, 2 days/week for 6 weeks in addition to compression therapy (CT)
Number of subjects: 24
Study 33423620 — intervention group
Group type: COMPARATOR
Intervention: Compression therapy (CT) only
Number of subjects: 24
Study 32377902 — intervention group
Group type: EXPERIMENTAL
Intervention: His bundle pacing
Number of subjects: 0
Study 32377902 — intervention group
Group type: EXPERIMENTAL
Intervention: Left bundle branch pacing
Number of subjects: 0
Study 35432020 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week online mindfulness intervention
Number of subjects: 53
Study 35432020 — intervention group
Group type: COMPARATOR
Intervention: waiting list control group
Number of subjects: 53
Study 32532356 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of dental pulp stem cells suspension (3.0x10^7 human DPSCs in 30ml saline solution) on days 1, 4, and 7
Number of subjects: 20
Study 32532356 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) on days 1, 4, and 7
Number of subjects: 20
Study 32532356 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine treatment for COVID-19
Number of subjects: 20
Study 35229631 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteral access sheath (UAS) 9.5F/11.5F (Group 1)
Number of subjects: 320
Study 35229631 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteral access sheath (UAS) 12F/14F (Group 2)
Number of subjects: 320
Study 35229631 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative ureteral stricture
Number of subjects: 320
Study 33581023 — intervention group
Group type: EXPERIMENTAL
Intervention: DePuy Synthes plate
Number of subjects: 100
Study 33581023 — intervention group
Group type: COMPARATOR
Intervention: VariAx plate
Number of subjects: 100
Study 36448255 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable polysaccharide hemostatic agent
Number of subjects: 136
Study 36448255 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hemostatic agent)
Number of subjects: 136
Study 33359194 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP ≤120 mm Hg
Number of subjects: 1481
Study 33359194 — intervention group
Group type: EXPERIMENTAL
Intervention: Each 10 mm Hg decrement in SBP
Number of subjects: 1481
Study 33359194 — intervention group
Group type: COMPARATOR
Intervention: SBP >120 mm Hg
Number of subjects: 1481
Study 34166312 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted sample design based on maternal HIV status and mortality
Number of subjects: 8
Study 34166312 — intervention group
Group type: COMPARATOR
Intervention: Geographically stratified 2-stage sample design
Number of subjects: 8
Study 35045119 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 600
Study 35045119 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 600
Study 35544149 — intervention group
Group type: EXPERIMENTAL
Intervention: MucoRice-CTB 6 g
Number of subjects: 60
Study 35544149 — intervention group
Group type: EXPERIMENTAL
Intervention: MucoRice-CTB (any dose)
Number of subjects: 60
Study 35544149 — intervention group
Group type: COMPARATOR
Intervention: Placebo (any dose)
Number of subjects: 60
Study 35920822 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded continuous glucose monitoring (CGM)
Number of subjects: 485
Study 35920822 — intervention group
Group type: EXPERIMENTAL
Intervention: Unblinded continuous glucose monitoring (CGM) after 1 week
Number of subjects: 485
Study 35920822 — intervention group
Group type: EXPERIMENTAL
Intervention: Unblinded continuous glucose monitoring (CGM) after 2 weeks
Number of subjects: 485
Study 35920822 — intervention group
Group type: EXPERIMENTAL
Intervention: Unblinded continuous glucose monitoring (CGM) after 3 months
Number of subjects: 485
Study 35920822 — intervention group
Group type: EXPERIMENTAL
Intervention: Unblinded continuous glucose monitoring (CGM)
Number of subjects: 485
Study 35171084 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential current (IFC)
Number of subjects: 60
Study 35171084 — intervention group
Group type: COMPARATOR
Intervention: Sham IFC
Number of subjects: 60
Study 34437410 — intervention group
Group type: EXPERIMENTAL
Intervention: Condensed RT (4 sessions/week for 6 weeks)
Number of subjects: 36
Study 34437410 — intervention group
Group type: EXPERIMENTAL
Intervention: Distributed RT (2 sessions/week for 12 weeks)
Number of subjects: 36
Study 32141273 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and Sleep Optimization (ExS)
Number of subjects: 23
Study 32141273 — intervention group
Group type: COMPARATOR
Intervention: Exercise only (Ex)
Number of subjects: 23
Study 36130057 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Awareness Practices (MAPs)
Number of subjects: 247
Study 36130057 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivorship Education (SE)
Number of subjects: 247
Study 36130057 — intervention group
Group type: COMPARATOR
Intervention: Wait-list Control (WLC)
Number of subjects: 247
Study 33403743 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) assistance to mini-punch grafting (MPG)/phototherapy
Number of subjects: 34
Study 33403743 — intervention group
Group type: COMPARATOR
Intervention: Mini-punch grafting (MPG)/phototherapy
Number of subjects: 34
Study 33403743 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-assisted method
Number of subjects: 34
Study 33403743 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (MPG/phototherapy and PRP-assisted)
Number of subjects: 34
Study 35731529 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) 1000 mg on days 1 and 15, 500 mg maintenance at months 12 and 18
Number of subjects: 42
Study 35731529 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ARAs
Number of subjects: 42
Study 35731529 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without ARAs
Number of subjects: 42
Study 35731529 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-desmoglein 3 antibodies (DSG3 Abs) levels
Number of subjects: 42
Study 35731529 — intervention group
Group type: EXPERIMENTAL
Intervention: RTX concentration
Number of subjects: 42
Study 35731529 — intervention group
Group type: EXPERIMENTAL
Intervention: B-cell depletion
Number of subjects: 42
Study 35731529 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-desmoglein 3 Abs levels
Number of subjects: 42
Study 33054842 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 120
Study 33054842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 34039025 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve repair (TMVr) with the MitraClip
Number of subjects: 614
Study 34039025 — intervention group
Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT)
Number of subjects: 614
Study 32024533 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial administration of 177Lu-DOTATATE
Number of subjects: 26
Study 32024533 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of 177Lu-DOTATATE
Number of subjects: 26
Study 32091613 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐emptive intrathecal morphine
Number of subjects: 90
Study 32091613 — intervention group
Group type: EXPERIMENTAL
Intervention: Post‐operative intrathecal morphine
Number of subjects: 90
Study 32091613 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (Group I)
Number of subjects: 90
Study 32091613 — intervention group
Group type: EXPERIMENTAL
Intervention: Post‐operative intrathecal morphine (Group III)
Number of subjects: 90
Study 32091613 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐emptive intrathecal morphine (Group II)
Number of subjects: 90
Study 33669174 — intervention group
Group type: EXPERIMENTAL
Intervention: PediaFit 1.1 (n = 24)
Number of subjects: 103
Study 33669174 — intervention group
Group type: EXPERIMENTAL
Intervention: PediaFit 1.2 (n = 30)
Number of subjects: 103
Study 33669174 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 49)
Number of subjects: 103
Study 34559185 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath‐O Correct lenses worn overnight for 3 months
Number of subjects: 31
Study 34559185 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31
Study 32131801 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional management of carious lesions and prevention (C + P)
Number of subjects: 31
Study 32131801 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological management of carious lesions and prevention (B + P)
Number of subjects: 31
Study 32131801 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention alone (PA)
Number of subjects: 31
Study 35290464 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 15081
Study 35290464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15081
Study 35290464 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (sensitivity analysis)
Number of subjects: 15081
Study 33962762 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate (2400 mg) administered concomitantly with roxadustat (200 mg)
Number of subjects: 84
Study 33962762 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium acetate (1900 mg) administered concomitantly with roxadustat (200 mg)
Number of subjects: 84
Study 33962762 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat (200 mg) administered 1 hour before sevelamer carbonate
Number of subjects: 84
Study 33962762 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat (200 mg) administered 1 hour after sevelamer carbonate
Number of subjects: 84
Study 33962762 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat (200 mg) administered 1 hour before calcium acetate
Number of subjects: 84
Study 33962762 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat (200 mg) administered 1 hour after calcium acetate
Number of subjects: 84
Study 33962762 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat (200 mg) administered 2 to 3 hours after sevelamer carbonate
Number of subjects: 84
Study 33962762 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat (200 mg) administered 2 to 3 hours after calcium acetate
Number of subjects: 84
Study 35654369 — intervention group
Group type: COMPARATOR
Intervention: Constant-load exercise (CLE)
Number of subjects: 55
Study 34641865 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits to pregnant women and their spouses every 2 months during pregnancy, with a follow-up visit 12-18 months after birth.
Number of subjects: 6905
Study 32417502 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 0
Study 32417502 — intervention group
Group type: EXPERIMENTAL
Intervention: Kyphoplasty
Number of subjects: 0
Study 32417502 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based kyphoplasties
Number of subjects: 0
Study 35748625 — intervention group
Group type: EXPERIMENTAL
Intervention: modified Attachment Behavioral Catch‐up (mABC)
Number of subjects: 36
Study 35748625 — intervention group
Group type: COMPARATOR
Intervention: modified Developmental Education for Families (mDEF)
Number of subjects: 36
Study 32100576 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (15 minutes, twice a week)
Number of subjects: 25
Study 32100576 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 25
Study 32100576 — intervention group
Group type: COMPARATOR
Intervention: Control group (RT alone without acupuncture)
Number of subjects: 25
Study 36305696 — intervention group
Group type: EXPERIMENTAL
Intervention: OLZ/SAM
Number of subjects: 0
Study 36305696 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 0
Study 34281145 — intervention group
Group type: EXPERIMENTAL
Intervention: Bullying involvement (perpetrators, victims, bully-victims)
Number of subjects: 4469
Study 34281145 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual factors
Number of subjects: 4469
Study 34281145 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer factors
Number of subjects: 4469
Study 34281145 — intervention group
Group type: EXPERIMENTAL
Intervention: School factors
Number of subjects: 4469
Study 33239012 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) viral load testing
Number of subjects: 55
Study 33239012 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-shifting to enrolled nurses
Number of subjects: 55
Study 33239012 — intervention group
Group type: EXPERIMENTAL
Intervention: POC VL testing and task-shifting combined
Number of subjects: 55
Study 33504897 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted increased gene expression of 12 genes associated with glioma risk.
Number of subjects: 7400
Study 33504897 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue-specific eQTLs from brain tissues.
Number of subjects: 7400
Study 33504897 — intervention group
Group type: EXPERIMENTAL
Intervention: MR and colocalisation approach.
Number of subjects: 7400
Study 33504897 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of MR estimates in brain and blood.
Number of subjects: 7400
Study 32833564 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotersen (TEGSEDI™)
Number of subjects: 0
Study 35962349 — intervention group
Group type: EXPERIMENTAL
Intervention: Zishen Pingchan granules (ZPG)
Number of subjects: 200
Study 35962349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 34434911 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention to promote cycling to school, involving 27 behavior change techniques over a 12-week practical phase and an 8-week preparatory phase.
Number of subjects: 250
Study 32112140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab 0.5 mg
Number of subjects: 31
Study 32112140 — intervention group
Group type: COMPARATOR
Intervention: Focal and peripheral laser treatment
Number of subjects: 31
Study 32112140 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 31
Study 32112140 — intervention group
Group type: COMPARATOR
Intervention: Laser treatment
Number of subjects: 31